Clinical Determinants of Disease Progression in Patients With Limb Girdle Muscular Distrophy Type 2E (NeuroLGMD2E)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04509609|
Recruitment Status : Recruiting
First Posted : August 12, 2020
Last Update Posted : August 12, 2020
A retrospective observational study that will enable us to collect retrospective data from the clinical records of LGMD 2E patients in order to highlight any possible correlation between:
- clinical variables and patient age,
- clinical variables and other clinical variables,
- clinical variables and clinical outcomes. The study will help to define the natural history of this rare disease and to ameliorate the management of these patients.
|Condition or disease||Intervention/treatment|
|LGMD2E||Other: Exon 3 truncating mutation Other: Any other mutation in SGBC gene|
Retrospective observational study. Retrospective data from clinical charts of patients affected by LGMD 2E will be collected after the subscription of informed consent.Data considered will include any clinical variable measured, both objective and subjective. All data obtained will be anonimized before any treatment. Data will be grouped according to the age of the patient, in order to have more data for each age and to gain a trustable description of the disease progression. The possible correlation of each variable to age, to other variables and to objective clinical outcomes will be studied. Clinical outcomes considered will include age of loss of deambulation, age of introduction of respiratory assist, age of introduction of cardiological therapy. Data collected will also be divided in two groups according to different genetic diagnosis in order to evaluate phenotipical differences of genotypical clesses. First group will count all patient with the truncating mutation c.377_384duplCAGTAGGA in exon 3, both in heterozigosis and in homozigosis Second group will include all the other patients.
Both on the global data collection and on data divided according to genotype, statistical analysis will be performed. Those analysis will study linear regression both with the univariate, bivariate and multivariate model.
|Study Type :||Observational|
|Estimated Enrollment :||33 participants|
|Official Title:||Clinical Determinants of Disease Progression in Patients With Limb Girdle Muscular Distrophy Type 2E|
|Actual Study Start Date :||June 1, 2020|
|Estimated Primary Completion Date :||September 30, 2020|
|Estimated Study Completion Date :||September 30, 2020|
LGMD 2E with a genetic diagnosis
Any patient affected by LGMD 2E with a genetic diagnosis
Other: Exon 3 truncating mutation
Any patient affected by LGMD 2E with a genetic diagnosis carrying the truncating mutation c.377_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
Other: Any other mutation in SGBC gene
Any patient affected by LGMD 2E with a genetic diagnosis other than the truncating mutation c.377_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
- Natural history [ Time Frame: december 2020 ]The clinical progression of the disease will be studied considering for each clinical variable its evolution according to patients' ages. This both in overall cohort and in genetic subgroups.
- Guidelines [ Time Frame: december 2020 ]The collection of clinical variables describing the progression of the disease will enable a better clinical management of these patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04509609
|IRCCS Ca' Granda Ospedale Maggiore Policlinico||Recruiting|
|Milano, Italy, 20122|
|Contact: Yvan Torrente +39 025503874 firstname.lastname@example.org|